Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)
$1,318.00
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 179.8 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5–44 years worldwide, and forecasts that number to increase to 189.0 million prevalent cases by 2028.
- The worldwide prevalence of ADHD among children aged 5–19 years is estimated to be 5.29%, while the prevalence among adults aged 20–44 years is estimated to be 2.80%.
- Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor. The vast majority of approved therapies are administered via the oral route.
- The highest proportion of industry-sponsored drugs in active clinical development for ADHD are in Phase II, with two drugs in the NDA/BLA stage.
- Therapies in development for ADHD focus on a wide variety of targets. All pipeline drugs for ADHD are administered via the oral route.
- High-impact upcoming events for drugs in the ADHD space comprise topline Phase I/II trial results, pivotal efficacy study results, estimated PDUFA dates, an expected patent expiration, and a meeting with the FDA.
- The overall likelihood of approval of a Phase I ADHD asset is 11.4%, and the average probability a drug advances from Phase III is 72.2%. Drugs, on average, take 9.0 years from Phase I to approval, compared to 8.9 years in the overall psychiatry space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for ADHD have been in the late phases of development, with 54% in Phase III–IV, and 46% in Phase I–II.
- The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the ADHD space is dominated by completed trials. Takeda has the highest number of completed clinical trials for ADHD, with 158 trials.
- Takeda leads industry sponsors with the highest overall number of clinical trials for ADHD, followed by Eli Lilly
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Non-pharmacological therapy
9 Pharmacological therapy
11 EPIDEMIOLOGY
14 MARKETED DRUGS
20 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 SPN-810 for ADHD (February 25, 2020)
28 SPN-810 for ADHD (December 9, 2019)
30 SPN-810 for ADHD (November 5, 2019)
32 Multiple Drugs for ADHD (September 4, 2019)
33 Vafidemstat for ADHD (April 25, 2019)
35 Monarch eTNS system for ADHD (April 19, 2019)
37 SPN-812 for ADHD (March 28, 2019)
39 AEVI-001 for ADHD (January 2, 2019)
40 SPN-812 for ADHD (December 20, 2018)
42 SPN-812 for ADHD (December 6, 2018)
45 KEY UPCOMING EVENTS
46 KEY REGULATORY EVENTS
46 Lannett Rolls Out US Adderall XR Rival
46 KemPharm Seeks Clearance Of D-Methylphenidate Prodrug
46 Supernus ADHD NDA Repurposes Old European Antidepressant
47 PROBABILITY OF SUCCESS
48 LICENSING AND ASSET ACQUISITION DEALS
48 Teijin Gains Japanese Rights To NeuroSigma’s Monarch eTNS Device For ADHD
48 KemPharm Offloads Two ADHD Candidates To Gurnet Point
48 Shionogi Licenses Akili’s Digital Medicine Candidates For ADHD, ASD
49 REVENUE OPPORTUNITY
51 CLINICAL TRIAL LANDSCAPE
52 Sponsors by status
53 Sponsors by phase
54 Recent events
55 BIBLIOGRAPHY
56 Prescription information
58 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in Prevalent Cases of ADHD, 2019–28
20 Figure 2: Overview of pipeline drugs for ADHD in the US
21 Figure 3: Pipeline drugs for ADHD, by company
21 Figure 4: Pipeline drugs for ADHD, by drug type
21 Figure 5: Pipeline drugs for ADHD, by classification
28 Figure 6: SPN-810 for ADHD (February 25, 2020): Phase III – CHIME 2 (Pediatric)
30 Figure 7: SPN-810 for ADHD (December 9, 2019): Phase III – CHIME 1 (Pediatric)
32 Figure 8: SPN-810 for ADHD (November 5, 2019): Phase III – CHIME 1 (Pediatric)
35 Figure 9: Vafidemstat for ADHD (April 25, 2019): Phase IIa – REIMAGINE (Spain)
39 Figure 10: SPN-812 for ADHD (March 28, 2019): Phase III – P304 (High Dose Adolescents)
40 Figure 11: AEVI-001 for ADHD (January 2, 2019): Phase II – ASCEND Part A (w/ mGluR Mutations Ages 6-17 Years), Phase II -ASCEND Part B (w/o mGluR Mutations, Ages 6 to 17 Years)
42 Figure 12: SPN-812 for ADHD (December 20, 2018): Phase III – P302 (Low Dose Adolescents)
44 Figure 13: SPN-812 for ADHD (December 6, 2018): Phase III – P301 (Low Dose Children), Phase III – P303 (High Dose Children)
45 Figure 14: Key upcoming events in ADHD
47 Figure 15: Probability of success in the ADHD pipeline
51 Figure 16: Clinical trials in ADHD
51 Figure 17: Top 10 drugs for clinical trials in ADHD
52 Figure 18: Top 10 companies for clinical trials in ADHD
52 Figure 19: Trial locations in ADHD
53 Figure 20: ADHD trials status
54 Figure 21: ADHD trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent Cases of ADHD, 2019–28
15 Table 2: Marketed drugs for ADHD
23 Table 3: Pipeline drugs for ADHD in the US
27 Table 4: SPN-810 for ADHD (February 25, 2020)
28 Table 5: SPN-810 for ADHD (December 9, 2019)
31 Table 6: SPN-810 for ADHD (November 5, 2019)
33 Table 7: Multiple Drugs for ADHD (September 4, 2019)
34 Table 8: Vafidemstat for ADHD (April 25, 2019)
36 Table 9: Monarch eTNS system for ADHD (April 19, 2019)
38 Table 10: SPN-812 for ADHD (March 28, 2019)
40 Table 11: AEVI-001 for ADHD (January 2, 2019)
41 Table 12: SPN-812 for ADHD (December 20, 2018)
43 Table 13: SPN-812 for ADHD (December 6, 2018)
49 Table 14: Historical global sales, by drug ($m), 2014–18
50 Table 15: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Spinal Motion Preservation Devices Market 
Sign up to the